Trial Profile
Neurodegeneration as an early event in the Pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomised controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest diabetic retinopathy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Brimonidine (Primary) ; Somatostatin (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms EUROCONDOR
- Sponsors BCN Peptides
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 23 Nov 2013 Accrual to date is 107% according to United Kingdom Clinical Research Network.
- 19 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.